Ariad Pharmaceuticals Enterprise Value:
2.666B for May 20, 2013Ariad Pharmaceuticals Historical Enterprise Value Data
Pro Data ExportThere is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| May 20, 2013 | 2.666B |
| May 17, 2013 | 2.666B |
| May 16, 2013 | 2.629B |
| May 15, 2013 | 2.749B |
| May 14, 2013 | 2.918B |
| May 13, 2013 | 2.769B |
| May 10, 2013 | 2.602B |
| May 9, 2013 | 2.638B |
| May 8, 2013 | 2.712B |
| May 7, 2013 | 2.828B |
| May 6, 2013 | 2.791B |
| May 3, 2013 | 2.739B |
| May 2, 2013 | 2.798B |
| May 1, 2013 | 2.747B |
| April 30, 2013 | 2.886B |
| April 29, 2013 | 2.909B |
| April 26, 2013 | 2.932B |
| April 25, 2013 | 2.914B |
| April 24, 2013 | 2.864B |
| April 23, 2013 | 3.023B |
| April 22, 2013 | 3.004B |
| April 19, 2013 | 3.039B |
| April 18, 2013 | 2.932B |
| April 17, 2013 | 2.956B |
| April 16, 2013 | 2.879B |
| April 15, 2013 | 2.874B |
| April 12, 2013 | 2.969B |
| April 11, 2013 | 2.920B |
| April 10, 2013 | 2.934B |
| April 9, 2013 | 2.809B |
| April 8, 2013 | 2.773B |
| April 5, 2013 | 2.705B |
| April 4, 2013 | 2.734B |
| April 3, 2013 | 2.682B |
| April 2, 2013 | 2.814B |
| April 1, 2013 | 2.966B |
| March 28, 2013 | 3.159B |
| March 27, 2013 | 3.201B |
| March 26, 2013 | 3.157B |
| March 25, 2013 | 3.207B |
| March 22, 2013 | 3.398B |
| March 21, 2013 | 3.459B |
| March 20, 2013 | 3.595B |
| March 19, 2013 | 3.676B |
| March 18, 2013 | 3.755B |
| March 15, 2013 | 3.845B |
| March 14, 2013 | 3.916B |
| March 13, 2013 | 3.902B |
| March 12, 2013 | 3.891B |
| March 11, 2013 | 3.874B |
About Enterprise Value
Click "Learn More" below to see how YCharts calculates Enterprise Value.
Enterprise Value (EV) is a valuation metric alternative to traditional market capitalization that reflects the market value of an entire business. Like market cap, EV is a measure of what the market believes a company is worth. Enterprise value captures the cost of an entire business, including debt and equity. It is a sum of claims of all preferred shareholders, debt holders, security holders, common equity holders, and minority shareholders - unlike market cap, which only captures the total value of common equity securities.
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Learn More
ARIA Enterprise Value Benchmarks
| Companies | |
|---|---|
| Array BioPharma | 673.05M |
| Celldex Therapeutics | 853.92M |
| Insmed | 275.02M |
ARIA Enterprise Value Rankings
| Overall |
82nd percentile 1407 of 8002 |
| Sector |
82nd percentile 114 of 650 in Healthcare |
| Industry |
90th percentile 22 of 237 in Biotechnology |
ARIA Enterprise Value Range, Past 5 Years
| Minimum | 17.70M | Dec 30 2008 |
| Maximum | 3.984B | Oct 5 2012 |
| Average | 1.121B |
